Overview of the European and North American studies on HPV testing in primary cervical cancer screening.
Jack Cuzick,Christine Clavel,Karl Ulrich Petry,Chris J.L.M. Meijer,Heike Hoyer,Sam Ratnam,Anne Szarewski,Philippe Birembaut,Shalini L Kulasingam,Peter Sasieni,Thomas Iftner +10 more
TLDR
The results support the use of HPV testing as the sole primary screening test, with cytology reserved for women who test HPV positive, with large demonstration projects needed to fully evaluate this strategy.Abstract:
Several studies suggest that HPV testing is more sensitive than cytology in primary cervical screening. These studies had different designs and were reported in different ways. Individual patient data were collected for all European and North American studies in which cytology was routinely performed and HPV testing was included as an additional parallel test. More than 60,000 women were included. The sensitivity and specificity of HPV testing were compared with routine cytology, both overall and for ages <35, 35–49 and 50+. The age-specific prevalence of high risk HPV (hr-HPV) was also analysed. HPV testing was substantially more sensitive in detecting CIN2+ than cytology (96.1% vs. 53.0%) but less specific (90.7% vs. 96.3%). The sensitivity of HPV testing was similar in all studies carried out in different areas of Europe and North America, whereas the sensitivity of cytology was highly variable. HPV sensitivity was uniformly high at all ages, whereas the sensitivity of cytology was substantially better in women over the age of 50 than in younger women (79.3% vs. 59.6%). The specificity of both tests increased with age. Positivity rates for HPV testing in women without high-grade CIN were region dependent. These results support the use of HPV testing as the sole primary screening test, with cytology reserved for women who test HPV positive. Large demonstration projects are needed to fully evaluate this strategy. © 2006 Wiley-Liss, Inc.read more
Citations
More filters
Journal ArticleDOI
New insights into cervical cancer screening.
TL;DR: In this article, the role of the human papillomavirus (HPV) DNA testing as an alternative screening tool, the impact of the HPV vaccine on screening, and future directions in cervical cancer screening are discussed.
Journal ArticleDOI
Analytical Comparison of the cobas HPV Test with Hybrid Capture 2 for the Detection of High-Risk HPV Genotypes
Maria Luisa Mateos Lindemann,Mario Jose Rodriguez Dominguez,Jesús Chacón de Antonio,Maria Teresa Sandri,Alessio Tricca,Mario Sideri,Hacène Khiri,Sophie Ravet,Sean Boyle,Carrie Aldrich,Philippe Halfon +10 more
TL;DR: The cobas HPV Test demonstrates comparable analytical performance to the HC2 test, but with a lower rate of cross-reactivity with lrHPV genotypes, and has the advantage of simultaneously providing HPV16/HPV18 identification.
Journal ArticleDOI
Comparison of Clinical Performance of Abbott RealTime High Risk HPV Test with That of Hybrid Capture 2 Assay in a Screening Setting
Francesca Carozzi,Elena Burroni,Simonetta Bisanzi,Donella Puliti,Massimo Confortini,P Giorgi Rossi,C. Sani,Aurora Scalisi,Francesco Chini +8 more
TL;DR: The noninferiority score test revealed that the clinical sensitivity and specificity of the Abbott RealTime HR HPV test were not inferior to those of HR HC2, and this test fully satisfies the requirements of a primary cervical cancer screening test.
Journal ArticleDOI
Prevalence and type distribution of high-risk human papillomavirus infection in women undergoing voluntary cervical cancer screening in Italy.
Alberto Agarossi,Enrico Ferrazzi,Fabio Parazzini,Fabio Parazzini,Carlo Federico Perno,L. Ghisoni +5 more
TL;DR: There was a substantial presence of HPV genotypes against which the vaccines available currently have shown cross‐protection efficacy, and these findings may contribute to reliable predictions on the potential efficacy of an HPV vaccine in clinical practice.
Journal ArticleDOI
Role of HPV Genotype, Multiple Infections, and Viral Load on the Risk of High-Grade Cervical Neoplasia.
TL;DR: The ability to identify women at higher risk of CIN2+ and CIN3+ based on both HPV genotype and viral load could be important for individualizing triage plans, particularly as HPV becomes the primary screening test.
References
More filters
Journal ArticleDOI
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.
Jan M. M. Walboomers,M. V. Jacobs,M. M. Manos,Franz X. Bosch,J. A. Kummer,Keerti V. Shah,Peter J.F. Snijders,Julian Peto,Chris J.L.M. Meijer,Nubia Muñoz +9 more
TL;DR: The presence of HPV in virtually all cervical cancers implies the highest worldwide attributable fraction so far reported for a specific cause of any major human cancer, and the rationale for HPV testing in addition to, or even instead of, cervical cytology in routine cervical screening.
Journal ArticleDOI
Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study
Ciaran B J Woodman,Stuart Collins,Heather Winter,Andrew Bailey,John Ellis,Pat Prior,Marie Yates,Terry P. Rollason,Lawrence S. Young +8 more
TL;DR: The findings suggest that attempts to exploit the association between cervical neoplasia and HPV infection to improve effectiveness of cervical screening programmes might be undermined by the limited inferences that can be drawn from the characterisation of a woman's HPV status at a single point in time, and the short lead time gained by its detection.
Journal ArticleDOI
Relation of human papilloma virus status to cervical lesions and consequences for cervical-cancer screening: a prospective study
M A E Nobbenhuis,Jan M. M. Walboomers,Theo J.M. Helmerhorst,Lawrence Rozendaal,A. J. Remmink,Elle K.J. Risse,Hans C. van der Linden,Feja J. Voorhorst,Peter Kenemans,Chris J.L.M. Meijer +9 more
TL;DR: Persistent infection with high-risk human papillomavirus is necessary for development and maintenance of cervical intraepithelial neoplasia CIN 3, and all women with severe dyskaryosis should be referred to gynaecologists, whereas women with mild to moderate dysKaryosis ought to be referred only after a second positive test for high- risk human papillsomav virus at 6 months.
Journal ArticleDOI
Trends in mortality from cervical cancer in the nordic countries: association with organised screening programmes
TL;DR: Investigation of time trends in mortality from cervical cancer in Denmark, Finland, Iceland, Norway, and Sweden since the early 1950s supports the conclusion that organised screening programmes have had a major impact on the reduction in mortality in the Nordic countries.
Journal ArticleDOI
Management of women who test positive for high-risk types of human papillomavirus: The HART study
Jack Cuzick,Anne Szarewski,Heather Cubie,G Hulman,Henry C Kitchener,David Luesley,Euphemia McGoogan,Usha Menon,George Terry,Robert Edwards,Claire Brooks,Mina Desai,C Gie,Linda Lee Ho,Ian Jacobs,C Pickles,Peter Sasieni +16 more
TL;DR: Comparison of the detection rate and positive predictive values of HPV assay with cytology and the best management strategy for HPV-positive women found HPV testing was more sensitive than borderline or worse cytology but less specific for detecting CIN2+.
Related Papers (5)
Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial
HPV screening for cervical cancer in rural India.
Rengaswamy Sankaranarayanan,Bhagwan M. Nene,Surendra S Shastri,Kasturi Jayant,Richard Muwonge,Atul Budukh,Sanjay Hingmire,Sylla G. Malvi,Ranjit Thorat,Ashok Kothari,Roshan F. Chinoy,Rohini Kelkar,Shubhada Kane,Sangeetha Desai,Vijay R Keskar,Raghevendra Rajeshwarkar,Nandkumar S Panse,Ketayun A. Dinshaw +17 more